Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia
19 7월 2023 - 5:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, non-alcoholic steatohepatitis (NASH)
and obesity, today announced it will host a virtual key opinion
leader event to highlight the TERN-701 program and discuss advances
in the treatment landscape for chronic myeloid leukemia (CML).
The event will be led by Emil Kuriakose, M.D.,
chief medical officer, oncology, at Terns and will feature
presentations and discussion with:
- Jorge Cortes, M.D.,
Director, Georgia Cancer Center, Augusta University
- Michael Mauro, M.D., Leader,
Myeloproliferative Neoplasms Program, Memorial Sloan Kettering
Cancer Center
Complete speaker biographies can be found on the
Event registration page here.
Event details are as follows:
Advances in the Treatment Landscape for
Chronic Myeloid LeukemiaDate and Time: July 25th, 2023 at
11:30 a.m. ET Webinar Link: Register
A webcast of the event will be available on the
investor relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcast will be archived
on Terns’ website for at least 30 days following the
presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, NASH and obesity.
Terns’ pipeline includes two clinical stage development programs
including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/-
an FXR agonist), and preclinical small-molecule GLP-1 receptor
agonist and GIPR modulator programs. For more information, please
visit: www.ternspharma.com.
Contacts for Terns
Investorsinvestors@ternspharma.com
MediaJenna UrbanBerry &
Company Public Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Terns Pharmaceuticals (NASDAQ:TERN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024